Swiss National Bank Has $1.60 Million Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Swiss National Bank increased its position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 38.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 68,600 shares of the company's stock after acquiring an additional 19,000 shares during the period. Swiss National Bank owned approximately 0.13% of Spyre Therapeutics worth $1,597,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Spyre Therapeutics in the 4th quarter worth approximately $46,000. Arizona State Retirement System grew its position in Spyre Therapeutics by 38.4% in the fourth quarter. Arizona State Retirement System now owns 10,115 shares of the company's stock worth $235,000 after buying an additional 2,805 shares during the last quarter. Intech Investment Management LLC bought a new position in shares of Spyre Therapeutics in the third quarter valued at $246,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Spyre Therapeutics in the fourth quarter valued at $290,000. Finally, MetLife Investment Management LLC lifted its position in shares of Spyre Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 20,132 shares of the company's stock valued at $592,000 after acquiring an additional 11,344 shares during the last quarter. 80.39% of the stock is owned by institutional investors and hedge funds.

Spyre Therapeutics Trading Up 1.2 %

NASDAQ:SYRE traded up $0.19 on Wednesday, hitting $15.49. 586,262 shares of the company's stock traded hands, compared to its average volume of 562,209. The company has a market cap of $933.38 million, a PE ratio of -2.07 and a beta of 2.98. Spyre Therapeutics, Inc. has a 1 year low of $14.90 and a 1 year high of $40.84. The firm has a 50-day moving average price of $20.19 and a 200-day moving average price of $25.30.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, beating analysts' consensus estimates of ($0.89) by $0.08. On average, research analysts forecast that Spyre Therapeutics, Inc. will post -4.46 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. The Goldman Sachs Group raised Spyre Therapeutics to a "strong-buy" rating in a research report on Tuesday, February 18th. Wedbush restated an "outperform" rating and set a $65.00 price objective on shares of Spyre Therapeutics in a report on Monday, January 13th. Finally, Wolfe Research started coverage on shares of Spyre Therapeutics in a research note on Tuesday, March 18th. They set an "outperform" rating and a $27.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $50.33.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).